Search

Meet Michaela Gruber, our December volunteer of the month

Can you tell us what you do for EHA and when you started?
Over six years ago, I was one of the initiators of what is now the “YoungEHA” and the “Young-EHA Committee”.

Read more

Meet Michaela Gruber, our December volunteer of the month

Can you tell us what you do for EHA and when you started?
Over six years ago, I was one of the initiators of what is now the “YoungEHA” and the “Young-EHA Committee”.

Read more

Meet Ton Hagenbeek, our May volunteer of the month

Anton Hagenbeek began as EHA Volunteer when EHA was only starting out. Below you will read more about his motivations and invites fresh blood to support the organization.

Read more

Meet Ton Hagenbeek, our May volunteer of the month

Anton Hagenbeek began as EHA Volunteer when EHA was only starting out. Below you will read more about his motivations and invites fresh blood to support the organization.

Read more

Membership

Change the world. Make a difference. Improve the lives of many. With more than 6,000 members from 150 countries, EHA is the largest European-based organization that caters to medical professionals, researchers, and scientists with an active interest in hematology.

Read more

Message from the EHA President

As the year closes, is with great pleasure that I reflect on 2021, six months into my Presidency of the European Hematology Association (EHA). It is also time to look forward to the new year.

Read more

Genome sequencing of thousands of patients with rare blood disorders

Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot. The genetic causes of dozens of such disorders are known (e. g.

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

Practical information

When do the meetings take place?The Spring Course will take place from 07-14 March 2025 in France. The first follow-up meeting will take place during the EHA2025 Congress from 12 – 15 June 2025.

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more